Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin

 Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin

Taro Terminates License and Co-Development Agreement with NovaBiotics for Novexatin

Shots:

  • The termination is based on results from P-IIb study, assessing Novexatin vs PBO, which was unable to meet a main goal of study under FDA guidelines with no superiority over PBO
  • In 2013, Taro entered into license and co-development agreement with NovaBiotics for its novel antifungal peptide Novexatin
  • Novexatin is a fast-acting topical drug candidate currently evaluated in P-IIb study for the treatment of fungal nail infections (onychomycosis)

Click here to read full press release/ article | Ref: Taro Pharmaceuticals  | Image: Taro

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post